Study of sacituzumab tirumotecan for low-grade bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low-grade bladder cancer that hasn't spread into the bladder muscle (called non-muscle invasive bladder cancer, or NMIBC).
- Your doctor can see at least one tumor during a cystoscopy (a camera test) within the past 12 weeks.
- Your cancer is considered intermediate risk, such as having more than one tumor, a tumor larger than 3 cm, or having had a previous low-grade tumor come back within a year.
- You have a performance status of 0 to 2, meaning you can still do daily activities with little to some help.
- You do not have high-grade bladder cancer or cancer that has spread to the bladder muscle or beyond.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a new drug (sacituzumab tirumotecan) for people with rare types of kidney or bladder cancer that have spread. The drug targets a protein called TROP-2 on cancer cells. The goal is to see if it can shrink tumors or slow the cancer when other treatments have stopped working or are not available.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.